Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Treasury Shares (2020 - 2026)

10x Genomics' Treasury Shares history spans 6 years, with the latest figure at $7.8 million for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 20.53% to $7.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.8 million, a 20.53% increase, with the full-year FY2025 number at $7.8 million, up 20.53% from a year prior.
  • Treasury Shares hit $7.8 million in Q4 2025 for 10x Genomics, down from $8.5 million in the prior quarter.
  • Over the last five years, Treasury Shares for TXG hit a ceiling of $9.2 million in Q2 2025 and a floor of $985386.0 in Q1 2021.
  • Historically, Treasury Shares has averaged $5.1 million across 5 years, with a median of $5.8 million in 2022.
  • Biggest five-year swings in Treasury Shares: skyrocketed 1591.53% in 2021 and later decreased 8.6% in 2023.
  • Tracing TXG's Treasury Shares over 5 years: stood at $1.3 million in 2021, then soared by 349.55% to $5.8 million in 2022, then decreased by 8.6% to $5.3 million in 2023, then rose by 21.73% to $6.5 million in 2024, then increased by 20.53% to $7.8 million in 2025.
  • Business Quant data shows Treasury Shares for TXG at $7.8 million in Q4 2025, $8.5 million in Q3 2025, and $9.2 million in Q2 2025.